Paul Varley, PhD, serves as Chief Development Officer at Alchemab Therapeutics, overseeing preclinical development, toxicology, CMC, and quality processes. With extensive experience at Kymab, AstraZeneca/MedImmune, and Cambridge Antibody Technology, he has contributed to key advancements in biological standards. A former British Pharmacopeia Commission member, he currently chairs a MHRA/BP Medicines group on biological medicine standards and serves on the European Pharmacopeia Expert Committee. Paul also advises the UK Vaccine Task Force on manufacturing. He holds a PhD in Biochemistry from the University of Newcastle upon Tyne and a first-class BSc in Biomolecular Sciences from Portsmouth Polytechnic.